On July 8, 2022 Median Technologies (ALMDT) (Paris:ALMDT) reported that the Company will be participating in the 2022 European Congress of Radiology (ECR), to be held in Vienna, Austria, July 13-17 (Press release, MEDIAN Technologies, JUL 8, 2022, View Source [SID1234616569]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Company will give an industry presentation and a scientific paper presentation. Details of the sessions include:
Industry presentation: "Enabling lung cancer screening with iBiopsy AI-based software as medical device"
Session: AIX Theater
Date: July 13, 2022
Time: 3:25 pm – 3:45 pm CEST
Scientific paper presentation: RPS 1305-6 – "Development and validation of a machine learning based CADx designed to improve patient management in lung cancer screening programmes"
Session: RPS 1305 – Artificial intelligence (AI) in chest imaging: part 2
Categories: Artificial Intelligence & Machine Learning, Imaging Informatics, Chest, Oncologic Imaging
Date: July 15, 2022
Time: 10:30 am – 12:00 pm CEST
Median’s team will be available at booth #AI-29, Expo X1, AI-area to discuss the presentations and present the latest developments on iBiopsy LCS CADe/CADx SaMD from July 13 to 17, 9:00 am-5:00 pm.
The European Congress of Radiology (ECR) organized by the European Society of Radiology (ESR) is the premier European event in radiology and the second largest in the world. The congress conveys more than 20,000 with a split of more than 10,000 professional delegates (radiologists, technologists etc.), and ~8,000 industry participants (imaging modalities, PACS etc.). Radiology professionals from Europe and beyond attend to gather knowledge through educational courses, to see the latest innovations presented by technical exhibitors, and to discover groundbreaking research from scientific paper presentations. More about the ECR: View Source
About iBiopsy: iBiopsy is based on the most advanced technologies in Artificial Intelligence (AI) and Data Science (DS), benefiting from Median’s expertise in medical image processing. iBiopsy targets the development of innovative AI/ML-based Software as Medical Device, to be used in several indications for which there are unmet needs regarding early diagnosis, prognosis and treatment selection in the context of precision medicine. iBiopsy currently focuses on lung cancer, liver cancer (HCC) and liver fibrosis (NASH).